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 Determining the efficacy of Complementary and Alternative Medicine (CAM) methods 
for the benefit of clinically diagnosed epileptic patients (ICD-10 code G40, definition found in 
Appendix) is imperative for developing funding strategies that support these methods, as well as 
for the success of promoting and improving education about these methods to achieve a truly 
multidisciplinary field of medicine. Additionally, CAM methods (i.e., ketogenic diets, 
comprehensive neurobehavior treatment (CNB), yoga, Ayurveda, botanicals, and 
electroencephalogram (EEG) biofeedback) benefit neurologic patients, the profession, 
practitioners, researchers, policy makers, and the public at large.1 Even with controlled seizures, 
epilepsy can present a host of issues that can hinder a child’s development and ability to function 
normally. Cognitive, behavioral, social, emotional, and other functionalities/abilities critical to 
normal development are all affected. There is limited research demonstrating efficacy of CAM 
therapies alone or coupled with that of an antiepileptic drug (AED). Further, it is unclear how 
consistent use of CAM therapies may impact the overall therapeutic success in pediatric epilepsy 
in the near future.   
 
Dozens of scientific publications exist on CAM methods and the overall impact on 
epilepsy. However, most of these studies were conducted in the past century and outside of 
North America, focused on adult patients, and included too few subjects to establish efficacy.  
With guidance from Covidence, this meta analysis reviewed seven of forty available publications 
that met the inclusion criteria for pediatric epileptic patients under the age of 25 years old who 
 
1 NIH. Complementary and Alternative Medicine (CAM). 2020 
  
 iii 
were treated with CAM therapies and monitored over a 12 month span within the United States 
between the years 2000 – 2021. 
 
All seven studies reported the use of CAM therapies such as keto diets, homeopathy / 
osteopathy, and comprehensive neurobehavioral treatment. The analysis of those studies revealed 
a statistically significant reduction in seizures for epileptic children utilizing CAM therapies (p = 
.0062 and p = .0059). The sample size of subjects was determined by article selection. A total of 
671 subjects, calculated from the 7 selected studies, were considered for evaluation. Of these, 
388 were excluded as they did not fit criteria for age and seizure duration or discontinued the use 
of CAM therapy. This exclusion resulted in a remainder of 283 subject participants. All subjects 
reported ≥ 50% reduction in seizure occurrence per month. Furthermore, 137 subjects (48%) 
reported complete seizure control. However, limited study size, small population, and a lack of 
long-term follow-up of treatment for pediatric epilepsy indicate the need for further research and 
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1. Introduction 
Epilepsy, the most common neurological disorder known to pediatricians and pediatric 
neurologists, affects 1% of children, and can have many adverse effects after its initial diagnosis. 
Epilepsy is primarily characterized by the tendency of unprovoked and reoccurring seizures that 
have no known etiology. Approximately 50 million people worldwide have been diagnosed with 
epilepsy, a chronic noncommunicable disease of the brain.2 Epileptic episodes can vary in 
severity and frequency, ranging from muscle spasms to prolonged convulsions that may present 
less than once per year to several times a day. 
 
The incidence of epileptic episodes is estimated to be five to eight new cases per 1000 
population by the age of 11, with nearly 50% of all epilepsy beginning under the age of 16 
years.3 The highest frequency of epileptic episodes occur within childhood, the period of life 
pragmatically defined as 14-18 years of age, and in the adulthood 30-65 years of age. When 
assessing an adolescent or adult with epileptic symptoms, an accurate diagnosis is critical as life-
changing consequences including cognitive impairment, declined neurologic functionality, 
neurotoxic adverse effects, and increased behavioral side effects, may result from an erroneous 
diagnosis45.   
 
As the cases of misdiagnosis of epilepsy occur with paroxysmal disorders, disorders in 
which symptoms develop abruptly and result in physical dysfunction, it is critical to understand 
 
2 World Health Organization. Epilepsy. 2019 
3 Panebianco et. al., Yoga for Epilepsy. Issue 10 & Appleton. Treatment of Childhood Epilepsy. 
 419-431 
4 Zupec-Kania & Spellman. An Overview of The Ketogenic Diet for Pediatric Epilepsy. 589-96 
5 Appleton, Epilepsy in the Teenager. 232-235 
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the disease difference of epilepsy in early childhood and epilepsy during adulthood. These 
differences are not only academic of value, they can also aid in diagnosis, treatment, and 
prognosis. R.E. Appleton outlines some vital differences between both age groups (Table 1).6 
 
Table 1. Differences Between Childhood and Adult Epilepsy  
1. Large differential diagnosis 
2. Heterogeneous condition 
a. Many epilepsy syndromes 
b. Many causes 
c. Many prognoses 
3. Most cases are idiopathic 
4. Not a static condition; evolves with age 
5. Not necessarily a chronic condition 
6. Unclear relationship between seizures and cognitive/behavioral difficulties 
7. Treatment must take account of educational issues and family dynamics 
8. Consideration of the adverse effects from AEDs on the immature, developing 
brain 
 
Patients clinically diagnosed with epilepsy have multiple treatment options available to 
them, including antiepileptic drugs (AED), surgery, and complementary and alternative medicine 
(CAM) therapies. CAM therapies are defined by both the National Center for Complementary 
and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH) and the National 
Center for Complementary and Integrative Health (NCCIH) of NIH as “a group of diverse 
medical and health care systems, practices, and products that are not presently considered to be 
part of conventional medicine”.7 NCCIH refers to the concepts of “alternative” and 
“complementary” differently:8 
• “If a non-mainstream practice is used together with conventional medicine, 
it’s considered “complementary. 
• If a non-mainstream practice is used in place of conventional medicine, it’s 
considered “alternative.” 
 
6 Appleton, Treatment of Childhood Epilepsy. 419-431 
7 Tabish, S. Complementary and Alternative Healthcare: Is it Evidence-based? V-IX 
8 NCCIH. Complementary, Alternative, or Integrative Health: What’s In a Name? 2018 
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With these definitions provided by the NCCIH, an appreciation of both the strengths and 
limitations of conventional medicine is necessary for the imminent development of conceptual 
integration models that can guide both public and private decision-making surrounding CAM 
research funding, research and practice. 
 
From their introduction in 1857, nearly 200 years ago, AED’s have shown their efficacy 
in the treatment of epilepsy. This has resulted in the identification and development of several 
iterations of AEDs. AEDs currently in use have improved tolerability and increased treatment 
options compared to previous formulations. Conventional medicine practitioners have dedicated 
decades to the development of allopathic treatments and research for neurological disorders such 
as AEDs, EEG, MRI, PET scans, vagus nerve stimulators, and brain surgery. However, not only 
can patients that present with similar symptoms experience a diverse set of reactions to or 
benefits from AEDs, but there is an absence of treatments that prevents the onset of epilepsy. 
Present-day researchers and clinicians have come to realize that to yield new pharmacological 
treatments in epilepsy, they must target therapies for specific subpopulations with drug-resistant 
epilepsy.9 
 
The broad variety of CAM therapies that are available can be categorized within eight subsidiary 
categories of complementary and alternative medicine. Nicole Hartmann et. al., list them as 
homeopathy, osteopathy, acupuncture, electroencephalography (EEG) biofeedback, naturopathic 
treatment, yoga, kinesiology, vitamins, and herbal remedies[reference]. Of the listed therapies, 
 
9 Privitera M. Epilepsy Treatment: A Futurist View. 2017 
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only three- ketogenic diet, immunoglobulins, and steroids- play substantial roles in the treatment 
of intractable childhood epilepsy due to having been studied more extensively. However, their 
impact on therapeutic success of seizure frequency reduction has not been adequately studied or 
documented. Despite the lack of scientific rigor in understanding their efficacy, mechanism of 
action, and safety, the three therapies introduced above have been partially accepted within 
medical doctrine. Until critical evaluation of alternative therapies is conducted, the medical 
community will continue to reject the implementation of alternative treatments. So far, studies on 
the use of the above-mentioned therapies have either: 1. Demonstrated clear efficacy and result 
in patients with an unclear mechanism of action, or 2. Displayed both unknown efficacy and 
mechanism of action.10,11,12,13,14 The intent of this analysis is to review the effect of CAM 
therapies on the overall quality of life of epileptic patients. 
 
Traditional epilepsy treatment relies  conventional pharmacological interventions such as 
levetiracetam, phenobarbital, and lorazepam in addition to epilepsy-related surgery such as 
temporal lobotomy. Despite the existence of more than thirty AED medications licensed and 
approved by the FDA for long-term treatment of epilepsy, nearly 40% of patients never achieve 
seizure freedom.15 Clinically diagnosed epileptic patients exposed only to conventional methods 
of treatment therefore run the risk of exposure to  adverse effects as well as not obtaining 
remission. Further, adolescent patients tend to experience more frequent adverse effects that limit 
 
10 Prasad et. al. Alternative Epilepsy Therapies: The Ketogenic Diet, Immunoglobulins, and Steroids. S81-S95  
11 Vining et. al. A Multicenter Study of the Efficacy of the Ketogenic Diet. 1433-1437 
12 DiMario and Holland. The ketogenic diet: A review of the experience at Connecticut Children’s Medical Center. 
2002 
13Kossoff et al. Efficacy of the ketogenic diet for infantile spasms. 2002 
14 Mady et al. The ketogenic diet: Adolescents can do it, too. 2003 
15 Hartmann et. al. Use of Complementary and Alternative Medicine (CAM) by Parents in their Children and 
Adolescents with Epilepsy – Prevalence, Predictors and Parents' Assessment. 11-19 
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their ability to work and participate in activities[reference], and can suffer from long-term side-
effects of high-dose and/or AED polytherapy, leading to major cognitive and behavioral 
difficulties.16  
 
Despite studies showing the negative impact that AED medications can have on 
behavioral and cognitive development of young adults, adolescents, and infants,4,5,9,17,18 these 
drugs remain as the mainstay course of treatment within the United States. Behavioral problems 
can range from mild to extremely severe under the influence of AED medications. The practice 
of polytherapy, the use of the use of two or more drug combinations with different mechanisms 
of action can also influence on the expression and severity of behavior problems. Levetiracetam, 
an approved antiepileptic drug used for treatment in both children and adults, has been associated 
with caused behavioral problems including aggression and changed mood states such as 
depression, agitation, hostility, irritability and hyperexcitability.19 Compared to nonusers, AED 
users have an increase in relative risk of death by 95%.20  Heavy reliance on monotherapy and 
polytherapy use of AEDs has resulted in increased mortality. Charlotte Figi, a patient who is 
refractory to available conventional treatments, exemplifies the therapeutic success of seizure 
frequency reduction by use of alternative methods, hence warranting for more funding to resume 
needed research.  
 
 
16 Kwan, M.D., & Brodie, M.D. Early Identification of Refractory Epilepsy. 314-319 
17 Loring, D., Cognitive Side Effects of Antiepileptics Drugs in Children. Vol XXII. Issue 10 
18 Cross, J., Neurodevelopmental effects of anti-Epileptic drugs. 1-10 
19 G. K Mbizvo. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. 2012 
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Born October 18th, 2006, Charlotte Figi came as a miracle healthy baby alongside her 
twin brother Chase Figi. At only the age of three months old, the life of baby Charlotte changed 
forever. Charlotte underwent her first seizure and, a week later, experienced another that lasted 
double the duration. Over the next few months, she frequently would have seizures lasting two to 
four hours and was hospitalized repeatedly. Medical tests accumulated up to nearly a million 
dollars. In the beginning, results displayed no signs of epilepsy and came back normal. Doctors 
were all stumped and could only discharge her.  
 
As time progressed, the seizures continued, and the hospital stays grew longer. Charlotte 
was prescribed seven or more heavy-duty antiepileptic and addictive medications, displaying 
cognitive and neurological declines. At the age of nearly three years old, Colorado’s Children’s 
Hospital neurologist tested her for the SCN1A gene in a rare, yet severe condition known as 
Dravet Syndrome. A few months later, results showed the presence of a mutation in the SCN1A 
gene. By the age of five, Charlotte suffered as many as 300 grand mal seizures a week, lost the 
ability to walk, talk, eat, and would go into repeated cardiac arrest. Even with the use of AEDs, 
Charlotte Figi displayed no improvement. With more dedicated funding allocated towards 
research into alternative treatment methods, patients with similar cases to Charlotte can be 
assisted.  
 
2. Review of the Literature 
There is high reliance on the use of monotherapy AEDs as the mainstay of treatment, as 
mentioned in findings by Lia Santulli and Elisabeth Halma, although correlations of efficacy and 
  
  
 7  
therapeutic success are disparate.2122 In contrast, a review performed by Edward Maa, Robert 
Caraballo, and Norman Doidge delivers empirical data and testimonial stories to suggest that 
CAM therapies and the introduction of neuroplasticity to the field of Neurology also displays 
success in the overall reduction and treatment of epilepsy.232425  
 
Advances in epilepsy treatment are occuring at a very rapid pace adding to the 
evolutionary field of medicine requiring practicioners, researchers, and healthcare providers to 
be at the forefront of acceptance to these changes. As healthcare providers struggle to keep up 
with current literatures and clinical work, inevitably, they often fail to exercise new trends and 
envision what the field of medicine could be in the near future.9 The seven studies analyzed 
within this systematic review equally combat against this delimma and demonstrates experts who 
challenge the normative pressures of western medicine.  
 
The issue of adverse effects is frequently underestimated, especially in children. Adverse 
effects in behavior and cognition, such as the previously mentioned, may lead to early 
discontinuation of AED medication treatment usage resulting in an increase in inadequate seizure 
control. Generally side effect severity is defined by an individual and not solely reliant on the 
clinician. Minimal side effects may be acceptable, with the result of good seizure control, 
whereas major side effects with or without seizure control are unacceptable.7 This individual 
response can be interpreted inversely from one individual, or family, to the next. Seizure control 
 
21 Santulli et. al., The Challenges of Treating Epilepsy with 25 Antiepileptic Drugs. 211-219 
22 Halma et. al., Behavioral Side-Effects of Levetiracetam in Children with Epilepsy: A Systematic Review. 685-691 
23 Maa et. al., The Case for Medical Marijuana in Epilepsy. 55(6) 783-786 
24 Caraballo, et al., Ketogenic Diet in Patients with Myoclonic-Astatic Epilepsy. 151-155 
25 Doidge. The Brain that Changes Itself: Stories of Personal Triumph from the Frontiers of Brain Science. 2007 
9 Privitera M. Epilepsy Treatment: A Futurist View. 2017 
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in children who experience severe or refractory epileptic occurrences typically achieve improved 
control by using doses of AEDs that produce loss of function and abilities, therefore, delaying 
learning composition.  R. E Appleton acknowledges, in many of these cases, a therapeutic 
compromise needs to be acquired whereby the major and head-injuring types of seizures are 
controlled without resulting in excessive sedation or loss of function.7 With the lack relative 
studies, in many cases, this therapeutic compromise may be difficult to achieve. Impaired 
functionality and learning capabilities can be avoided using CAM methods.  
 
This brief analysis will focus on some of the eight CAM therapies listed by Nicole 
Hartmann et al.7, including non-conventional medical treatments, dietary approaches, herbal 
remedies, yoga, osteopathy, and homeopathic treatments.  The evidence base for most non-
conventional treatment options is generally limited and restricted to non-randomized and 
retrospective studies.  
 
2.1 Ketogenic Diet 
 The effects of the ketogenic diet are similar to that of fasting in that the intake of  high fat 
and low carbohydrate content promotes prolonged ketone production.7 Before the development 
of AEDs for the treatment of epilepsy became popular and widespread, the ketogenic diet was 
the treatment of choice. In the 1990s, interest in ketogenic diets was reignited following 
prospective observational studies. Equally, intractable epilepsy and AED toxicity in children 
permitted the need for ketogenic diets as a less-invasive treatment.7 There are risks associated 
with ketogenic diets including gastrointestinal upset, risk of dehydration and hypernatremia, 
kidney stones and vitamin deficiencies if not frequently monitored.7 Despite these risks, children 
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treated with ketogenic diets showed improved cognition and behavior compared to adverse 
affects experienced from the use of AED’s. This can result from direct effect of reducing seizure 
frequency but also indirectly via the reduction of AED use. 7 
 
2.2 Herbal Remedy (Homeopathy) 
 Cannabis sativa has a long history of medicinal use as treatment for a variety of whole-
body ailments including rheumatism, pain, and convulsions.  Before its dismissal following the 
Marijuana Tax Act of 1937 and classification as an illegal substance, cannabis sativa was 
available throughout the U.S. at all pharmacies for the prescription of multiple maladies.23 
Cannabis sativa consists of 489 known components, 70 of which are cannabinoids, while the 
remainder are neuroactive substances. D-9- tetrahydrocannabinol (THC) and cannabidiol (CBD) 
are two of the most common cannabinoids. Multiple randomized studies evaluating THC 
efficacy conducted within the period of 1970 to 1985 displayed protection in cats and prevention 
in baboons from kindled seizures with the use of D-9-THC. In addition, 93% of the sample 
population exhibited partial or full convulsion improvement with the administration of CBD.21 
 
2.3 Yoga (Osteopathy) 
Osteopathic medicine is a discipline with emphasis on the interrelated unity of all 
systems in the body, a whole person approach to medicine. This approach focuses to treat the 
entire person rather than a single symptom. Practitioners of osteopathic medicine help patients to 
cultivate mindsets and lifestyles that fight and prevent illness. Yoga, similar to osteopathic 
 
23 Maa et. al., The Case for Medical Marijuana in Epilepsy. 55(6) 783-786 
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medicine, promotes the body’s natural tendency towards health and self-healing. Stress is known 
to be a leading factor for eliciting seizures and yoga aids by inducing relaxation.7   
2.4 Epilepsy and CAM 
Ketogenic diets were used as a CAM therapy in 90% of patients across the seven 
included studies (n=257). The remaining 10% was divided between osteopathic, homeopathic 
and CNB treatments.  Epilepsy is a multidimensional condition that includes multiple aspects of 
the patient and can affect various parts of a persons cognitive, behavioral, social functionality. 
Nearly half of the epilepsy diagnosed population suffer from refractory seizures which can be 
defined by the International League Against Epilepsy (ILAE) as the persistence of seizures on 
three or more antiepileptic drugs in full doasage and total compliance over a period of 3 years.  
 
 Most patients report that epilepsy negatively impacts their social life due to the stigma 
associated with this condition, while others feel discriminated against in their work 
environments. Recently, compliance with AED medications has surfaced as a problem for 
patients diagnosed with chronic epilepsy, especially for those who require long-term and life-
long therapy.  To illustrate this, Hartmann et al. obtained approval from the Ethics Committee to 
conduct a structured interview process on patients aged 0 to 18 years with the diagnosis 
“epilepsy” by ICD-10-GM code which refers to inpatient and outpatient diagnosis of epilepsy. 
Of the 21 patients included in their use of CAM therapy study, 17 (81%) reported experiencing 
adverse side effects (ADE) of anticonvulsants. The ADE reports included the following answers: 
concentration deficit/fatigue, behavior problems/aggressiveness, delay in speech development, 
enuresis, diplopic images, liver impairment, dry skin, coryza, cold limbs, and weakening of 
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immune system15. These factors contribute to the reasons why medication compliance is an issue 
and why patients diagnosed with epilepsy may seek help from CAM.  
 
The trend of using CAM for treating epilepsy does not differ from that in other medical 
conditions. Sirven et al.26 conducted a study where 50% of patients cited the use of CAM 
therapies for non-seizure conditions, while 44% turned to CAM therapies specifically for seizure 
reduction. The use of alternative treatments is evidently not only useful for epilepsy but can also 
complement treatment of other medical conditions with less harmful adverse effects. In a study 
of 143 patients with focal or generalized seizures treated with ketogenic diets, Maydell and 
colleagues27 found that approximately 48% of the patients demonstrated improved alertness, 
motor improvements, behavior improvements, sleep improvement and significant developmental 
progress with CAM therapy treatment. Additionally, the number and dosage of antiepileptic 
drugs required was reduced in relatively 50% of patients. Another study showed that amongst 
five children with epilepsy treated with CAM, primarily CNB, 100% had previously been treated 
with antiepileptic drugs.27 AED medication use ranged from phenytoin, lamictal, and valproate 
with dosages of 150 to 625mg/day. Results showed that AED medication(s) were either reduced 
significantly or unchanged for all patients. During the period of treatment with CAM methods, 
each patient underwent a quality of life (QOL) follow-up providing testimonials to their use of 
ketogenic diets.28 Testimony reports listed the ability to achieve academic adeptness, regain 
courage to drive again, become activists for children undergoing abuse, and decreased 
depression/anger.   
 
26 Sirven et al. Complementary/alternative medicine for epilepsy in Arizona. 576–577. 
27 Maydell et al. Efficacy of the ketogenic diet in focal versus generalized seizures. 2001 
28 Reiter and Andrews. A neurobehavioral approach for treatment of complex partial epilepsy: efficacy. 2000 
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In 2002, DiMario and Holland12 reported similar testimonies and presented results 
comparable in outcome with other reports mentioned. Their research observed that 71% of their 
18 patients experienced greated than 50% reduction in seizures, 17% of whom became seizure 
free within only the first 6 months of treatment. The etiology of children’s epilepsy varied 
between idiopathic and symptomatic epilepsy. None of the improvements were statistically 
found to be related to patient age (P=0.97), sex (P=0.78), or epilepsy etiology (P=0.80)12. 
DiMario et al. conducted follow-up reports which showed that the number or dosage of 
antiepileptic drug per patient decreased signficantly, with more patients becoming AED free by 
the first 12 months.  
 
Despite the limitations in sample population assayed, these studies suggest that there are 
a considerable number of patients affected by epilepsy who choose to try CAM therapies. All 
seven studies described in this analysis report data spanning a 12 - 24 month period of CAM 
method treatment. The Kossoff et al., 13 and Mady et. al.14 retrospective studies were the only to 
report data about patient seizure improvement and reduction every 3 months. At the 12-month 
mark, 36 of the 43 (87%) patients treated with CAM methods showed > 90% seizure reduction. 
20 of the 43 patients had a mean of 419 seizures per month (ranging between 2 - 3,000 
seizures/month). A positive change in seizure frequency for patients experiencing nearly 3,000 
seizures per month to greater than 90% reduction, by way of CAM methods is poignant. Such a 
tendency encourages us to look closer into the most popular CAM therapies and try to 
 
12 DiMario et al. 2002 
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understand their potential value. Ketogenic diets, CNB, and osteopathic/homeopathic therapies 
have proven themselves safe, and well-tolerated. 
3. Problem Statement 
3.1 Objective 
 This thesis systematically evaluated the therapeutic success of complementary and 
alternative medicine (CAM) methods as a treatment option for epileptic children. Of the multiple 
ways to define and monitor the impact of epilepsy on a patient’s QOL, assessments where the 
patients can record their feelings on seizure severity and frequency are particularly useful to 
document and display progress following  treatment changes. Data collected from patients and 
parents on the overall seizure control and effectiveness observed pre- and post- CAM therapy 
adoption was compared and tested for statistical significant differences It is critical to evaluate 
the effectiveness of CAM therapy treatment options as they can present tremendous 
improvements in behavioral and cognitive functionality.  
 
3.2 Description of the Research Objective 
The objective of this work was to determine the efficacy of CAM therapies on epilepsy 
by means of a meta-analysis. Various prospective studies have analyzed positive correlations 
between psychological health, therapeutic success, and physical health in epileptic patients. For 
the purpose of this study, due to limited data, the therapeutic success of CAM methods on 
pediatric patients ages 0-25 years diagnosed with epilepsy was the focus.   
 
3.3 Research Questions 
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 Non-pharmacological treatment of epilepsy can include surgery, diet alteration, body and 
mind stimulation, and other alternative therapies. This meta-analysis sought to answer the 
following questions: What can CAM therapies do for epileptic patients? What does statistical 
data display about the success rate in epileptic patients after adherence to CAM therapies? How 
do CAM therapies improve the patient’s life and reduce epileptic occurrences? 
 
4. Methodology 
A meta-analysis is the statistical procedure for assessing previous research studies to 
derive conclusions on a particular research matter. Decisions regarding the utility and validity of 
a given hypothesis for an alternative therapy or intervention on epileptic patients cannot be based 
on the results from a single study. Results typically vary from one study to the next. By 
performing this type of quantitative study design, review of a large, and often complex and 
conflicting body of literature can be consolidated and examined. A Chi Square test is a statistical 
procedure used to examine the differences between categorical variables within the same 
population. Chi square testing in a meta-analysis report assumes that all the studies are 
measuring an identical effect and provides a p-value to test the hypothesis. Independent sample t-
test are used to compare the means of two independent groups and determine if there is statistical 
evidence to indicate that the associated population means are significantly different.   
 
Meta-analysis can be applied in a host of diverse fields. Pharmaceutical companies, 
combined with regulatory agencies, use meta-analysis to gain approval of drugs. Clinicians and 
multidisciplinary researchers in medicine, education, psychology, and beyond use meta-analysis 
to determine efficacy of interventions and compare them to determine which ones work best. 
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Meta-analyses can play a pivotal role for researchers as they aid in identification of questions 
that may be answered and those that remain un-answered. This analysis will provide evidence for 
the need of more research in Pediatric Neurology with focus in epilepsy. Additionally, it will 
identify which outcome measures are most likely to yield significant results, and the 
corresponding variants that are likely to be most powerful.   
 
Statistical analyses were performed using the IBM SPSS Statistics 23. Multivariate 
analysis to study the relationship between sample population age, seizure reduction, and CAM 
usage was done using Chi-square test and independent t-test. Association between therapeutic 
success and CAM usage was analyzed using Chi-square test. Variables with p < 0.05 was 
considered statistically significant p value.  
 
A meta-analysis study was conducted on 283 patients diagnosed with epilepsy to evaluate 
their therapeutic success (reduction in epilepsy occurrence) resulting from the use of CAM 
therapies. Observations were made on the same subjects over a 12+ month span and collected 
from seven studies. The sample size was determined by article selection and based on the subject 
participation with a duration period of 12 months or more. Epilepsy patients within the United 
States, who were under 25 years of age, experienced more than 5 epilepsy occurrences, and had 
been using a CAM therapy for at least 12 months were included. 388 subjects were excluded; 
283 remained for evaluation. Although this study aimed to address the affect that CAM therapies 
can have on epileptic children’s life, appreciation for allopathic “western and conventional” 
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When a treatment method is inconsistent from one study to the next, meta-analysis 
identifies common effects. The examination of variability or heterogeneity within inconsistent 
study data is a critical outcome. Different meta-analyses are essential tools used to summarize 
and categorize empirical evidence that fits pre-specified eligibility criteria to answer a specific 
research question accurately and reliably. This type of analysis helps healthcare practitioners, 
clinicians, and researchers keep up to date on healthcare initiatives; provide policy makers with 
crucial information to aid in judgement of risks, benefits, and harms of healthcare interventions. 
For the purpose of evaluating health care interventions, a Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) flow diagram was used (see Figure 1.). The 
flow diagram depicts the flow of studies through different phases of a systematic review. It 
thoroughly delineates records identified, included, and excluded, and the reasons for exclusion.  
  
  





Articles were searched on the following search engines PubMed, EMBASE, NIH, 
Grants.gov, and Google Scholar. Primary articles involving CAM ketogenic diets, yoga, 
Ayurveda, botanicals, and EEG biofeedback were extracted, based on preliminary criteria such 
as year, geographic location, and the use of children under the age of 25, from the above-
mentioned databases. A database of selected articles was created from an exhaustive search using 
serval interfaces assessing all medical literature pertaining to pediatric epilepsy use of non-
pharmalogical treatment from 2000 to 2021. The term “epilepsy” was paired with the medical 
Figure 1. Prisma Transparent Reporting Of Systematic Reviews And Meta-Analyses 
  
  
 18  
subject key words “refractory epilepsy,” “neurologic condition,” and “seizures,” as well as the 
following terms: “focal seizures,” “children,” “adolescents,” “alternative methods,” and “CAM 
therapies.” 
 
The inclusion criteria were as follows to answer the research questions: sample size, age, 
gender, course of disease, ICD-10 codes if applicable, and frequency of Epileptic seizures (Table 
2). The data were based on content areas of study design, the type of CAM therapy performed, 
sample size, subject characteristics, and treatment duration. This meta-analysis did not involve 
the administration of a survey and in result did not need IRB approval. Covidence and Prism-P 
were used to aid in the managing of a systematic meta-analysis review. Once the combined 
articles were gathered based on the inclusion criteria, the above searches resulted in seven 
articles to be evaluated.  
 
4.1 Covidence  
A literature search and Covidence screening of forty articles found seven studies that met 
the inclusion criteria (Table 2) . This systematic meta-analysis review utilized Covidence to aid 
in the managing of a seamless review process and combine results, cacluate significance 
intervals (p value) and test heterogeneity of results, otherwise known as variability among 
studies.  
 
Covidence is a web-based software platform that streamlines the production of systematic 
reviews. After importing each reference using the RIS text format, a title and abstract, and full 
text review screening was independently conducted to eliminate publications that fell outside the 
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inclusion criteria parameters. Covidence allows for the collaboration of multiple reviewers to 
screen and comment on imported studies and vote on if they should or should not be included in 
the data extraction process. This portion of data collection was completed without the aid of 
others, henceforth screened independently.  
 
Table 2. Inclusion and Exclusion criteria for a cross-sectional study of CAM methods on clinically diagnosed 
pediatric patients with Epilepsy: Covidence 
Inclusion criteria Exclusion criteria 
Patients < 25 years of age Any acute or chronic condition that would limit the ability of the 
patient to participate in the study 
Diagnosis of Epilepsy Geographic location outside of the United States 
Sample Size < 2000 patients  Use of AED medications, surgery, or western medical treatments 
for Epilepsy 
Male and female participants Adults > 25 years of age 
ICD-10 Codes for Epilepsy Diagnosis Refusal to give informed consent 
Frequency of Epileptic episodes > 5 RTC studies > early 2000’s 
 
4.2 Article Selection for Meta-Analysis 
 Article selection was limited to primary research articles. Non-English articles, small 
sample size and geographic locations beyond the United States were excluded, as were articles 
focusing on only the use of AED treatments for epilepsy. Studies of adult patients, individuals 
older than 25 years of age, were also excluded. To be included, the article had to also have 
extractable data on patients who consistently used CAM therapies. That data must include the 
number of subjects, patients with sizable difference in the reduction of seizure frequency, age, 
patients with no change, and seizure type. 
 
 For the purposes of the meta-analysis, therapeutic success was defined as ³ 50% of 
reduction of Epileptic episodes. This percentage was tallied after a cumulated 12 months of 
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monitoring. Conversely, patients experiencing < 50% seizure reduction after 12 months were 
considered to have displayed some but not full therapeutic benefit. 
 
4.3 Meta-analysis of Diet, CNB & Homeopathy / Osteopathy Efficacy 
 Available empirical data fitting the inclusion criteria in Table 2 was analyzed to 
determine the overall efficacy of ketogenic diets, CNB, and homoeopathy / osteopathy methods. 
The following studies found in Table 3 reported the number of patients who continued to follow 
CAM therapy after a 12-month period vs. those who ceased therapy after an initial 3 months 
(referred to as discontinued). From the listed studies in Table 3, a meta-analysis was conducted 
to analyze the efficacy of keto diets, CNB, and homeopathy/osteopathy therapies on the overall 
therapeutic success in epileptic patients. The research synthesis process allowed for enhanced 
interpretation on whether the use of alternative medical treatment for epilepsy can result in 
improvement of seizure occurrence. A chi-squared test for the effect of heterogeneity, variability 
among studies, within the group of subjects who continued CAM therapy post 12-months was 
performed to denote if an intervention did or did not work similarly per patient or study. In doing 
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CPS= Complex Partial Seizures, GTC=Generalized Tonic-Clonic, and NR= Not Reported 
 
5. Data Analysis 
First, Covidence and PRISMA flowchart were used to screen 40 articles fitting the 
inclusion and exclusion criteria. When screening articles, Covidence prompts reviewers with the 
following sections: “identification”, “methods”, “population”, “interventions”, and “outcomes”. 
 
29 Vining et al. Growth of children on the ketogenic diet. 2002 
26 Maydell et al. Efficacy of the ketogenic diet in focal versus generalized seizures. 2001 
12 DiMario et al. 2002 
13 Kossoff et al. Efficacy of the ketogenic diet for infantile spasms. 2002 
14 Mady et al. The ketogenic diet: Adolescents can do it, too. 2003 
27 Reiter et al. 2002 
15 Hartmann et al. Use of Complementary and Alternative Medicine (CAM)… 11-19 
Table 3. Included Studies: Measurement of Responses 









Mady et al14 Reiter and 
Andrews27 
Hartman 
n et al.15 
Study Type Prospective Retrospective Retrospective 
102 (43%): 
Discontinued 
Retrospective Retrospective Retrospective Prospective 
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0.2 – 9.8 0.3 – 29.0 1.0 - 15.0 0.5 – 2.0 12.0 – 19.0 9.0 – 23.0 1.0 – 16.0 
CAM 
Therapy 
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Notes and in-depth commentary are made during this procedure. Second, after identifying 
records with useful data, information on the number of excluded articles, reasons for excluded 
articles, number of assessed articles and study demographics of the eligible studies was recorded 
(using PRISMA). This permitted the exporting of empirical data into .csv excel files to allow all 
notes from each study to be expressed in one sheet.  
 
While screening studies, the type of CAM therapy implemented, population size, age 
variation, seizure reduction frequencies, and the number of children completing 12 months of 
therapy were documented. IBM SPSS Software was used to analyze data and survey for 
heteroscedasticity. The null hypothesis of this thesis was that CAM methods do not present 
improvement in therapeutic outcome for clinically diagnosed children with epilepsy. If the null 
hypothesis is to be rejected, the alternative hypothesis is accepted. The alternative hypothesis for 
this study states that CAM therapy shows enhanced therapeutic outcome for epilepsy in children. 
The statistical significance between the seven selected studies was assessed using p-value.  
 
A p-value less than or equal to 0.05 indicates the statistical probability in which the test 
hypothesis should be rejected. The small p-value indicates evidence against the null hypothesis, 
as there is less than a 5% chance that the null is correct and therefore should be rejected.  
However, this does not mean that there is a 95% probability that the alternative hypothesis is 
true. A p-value greater than or equal to 0.05 is not statistically significant and indicates a higher 
probability to accept the null hypothesis. This means we retain the null hypothesis and reject the 
alternative hypothesis.  The process of testing a hypothesis is fundamental to statistical inference. 
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A null hypothesis represents a theory that is put forward “either because it is believed to be true 
or because it is used as a basis for argument but has not yet been proved. 
 
Empirical data results could aid in the conclusion of the testable hypothesis that 
complementary and alternative medicine therapies can successfully improve the overall quality 
of life for neurologic conditions such as epilepsy. In order to distinguish the therapeutic success 
in effectiveness of one CAM therapy compared to another, an independent t-test was 
performed.  Independent t-tests provide levels of significance which refers to the likelihood 
that a random sample is or is not representative of a given population. A t-test resulting in a 
population displaying statistical significance from the choice of CAM therapy and percentage of 
therapeutic success suggests there is less than one in a hundred chance of being wrong.   
 
A two-tailed t-test was executed on the collected studies 12-15,26-28 due to distinctive 
variabilities and sample sizes. The statistical power of the analysis is not as good because of 
limited data. Figure 2 exhibits the sum of children per CAM therapy (i.e., Keto, Homeo, & CNB) 
and seizure reduction percentage. Figure 2 depicts an easy visual of effectiveness per CAM 
therapy and sample size. This is important to display the lack of participants per CAM therapy 
which can affect any ultimate conclusions. While the data remains valuable, larger sample sizes 
would depict an even stronger result to draw conclusions from.  
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Varied populations shown in Figure 3 verifies the presence of heteroscedasticity, 
differences within a range of data. Heteroscedasticity is a statistical phrase that refers to the 
circumstance in which the variability of a variable is unequal across a range of values.  With a 
limited quantity of studies addressing the efficacy of CAM therapy utilization for the treatment 
of pediatric epilepsy, populations become varied, random, and statistical power is slightly offset. 
The statistical power, often referred to as sensitivity, is how likely the study is to distinguish an 
actual affect from one of chance. A statistical power that is slightly offset occurs when 
limitations in data introduced, limitations including available study quantity. Despite these 
characteristics of the data, a comparison between the reduction of seizure occurrence from 
ketogenic diets to homeopathy/osteopathy treatments resulted in a statistically significant effect 
of p-value of 0.0062. In addition, a p-value of 0.0059 resulted from the comparison between 
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6. Discussion of Data Results 
The therapeutic success of complementary and alternative medicine therapies on 
clinically diagnosed children with epilepsy is limited yet, very much desired for further research.  
With prevalent differences in variability and sample sizes per study, developing concrete 
conclusions can be more difficult, but still very attainable. This finding is consistent with 
previous research that determined there are not enough controlled studies demonstrating the 
efficacy of CAM therapies in the treatment of pediatric epilepsy.30 Hurt and his colleagues 
conclude their study warranting more research in order to study the effects of CAM therapies on 
epileptic children at a larger capacity.  
 
 












Vining et al Maydell et al DiMario and
Holland












Figure 3. Epilepsy Occurence Reduction % per study
< 50% 50 - 90% > 90% 100% Seizure Free
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6.2 Efficacy Over Time 
 Data from the seven studies were summarized to determine the efficacy of different CAM 
methods after 12 months (n=283). A large percentage of patients underwent the same treatment 
as displayed in Figure 4 with the breakdown of methods used within the included studies. 
Additionally, Figure 4 exemplifies clear evidence to why statistical power may not be as efficient 
due to the large sample size difference. Of the 238 patients, 137 (58%) were reported to have 
achieved complete seizure control and ³ 90% seizure control, respectively (see Table 3 and 
Figure 4). (Note that the figure for ³ 90% therapeutic success includes those with complete 
seizure control and does not include those who discontinued treatment.) This evidence proves 
that, despite limitations, CAM therapies can provide epileptic patients with hope, courage, 
strength, behavioral and cognitive control, and the ability to achieve flapping accolades in 
education. Statistical data exhibiting more than 50% of study participants with greater than 90% 







Figure 4. Methods of CAM used for Children with Epilepsy 
Used CAM Therapy (n = 283) Treated children, n (%) 
 
Keto Diet 257 (90) 
Homeopathy 14 (5) 
Osteopathy 12 (4.2) 
Comprehensive Neurobehavioral Treatment 5 (2) 
Naturopathy 4 (1.4) 
Yoga 4 (1.4) 
Vitamins 4 (1.4) 
Kinesiology 2 (.7) 
Chiropractic 2 (.7) 
Others 7 (2.5) 
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7. Limitations 
7.1 Limitations and Future Directions 
There are limitations of the current study that should be considered, as well as 
considerations for future research. First, these data are representative of a cohort of young and 
school-aged children with inconsistent diagnoses and frequency of epilepsy. Second, article 
selection and screenings were all completed independently. Covidence allows for colleagues to 
work concurrently to screen articles and make notes as to reason of exclusion. Single screening, 
as opposed to group screening, can allow for substantial studies to be missed.  Furthermore, 
statistical analysis conducted resulted from that of a heteroscedastic/unequal population. 
However, while findings from the current meta-analysis include subjects of infancy to the 
maximum age of 25 years old, it may not generalize to individuals with cognitive impairments 
and behavioral problems.  
Findings from the current study may not generalize to adolescents and young adults with 
epilepsy or children with developmental disabilities. Future research should incorporate patients 
spanning a broader developmental level to determine if the modifiable factors identified in this 
study are relevant. Moreover, most patients with little to no autonomy over their treatment 
options are subjected to parent-reported decisions. A psychosocial factor from the child’s 
perspective could be very critical for future research. This analysis only compared the effect of 
CAM therapies in chronic epilepsy on individual and family level influences and quality of life.  
Other modifiable and nonmodifiable factors, including aspects of the health care system 
(e.g., access to resources, patient-provider communication) and community, should be examined 
in the context of pediatric epilepsy adherence. Many families lack knowledge on available 
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alternative means of treatment for neurological conditions and medical disciplines due to the lack 
of dedicated research in the field. Current publications on CAM therapies for neurologic 
conditions are highly funded throughout the EU, South America, Middle East, and North Africa 
but not North America.  
Overall, there are a limited number of small studies, often with a lack of randomization, 
controls, and long-term follow-up. Many studies include statistical analyses to assess whether the 
observed changes were greater than chance alone, and few studies have directly compared 
different CAM therapy methods to each other. Methodologies were not consistent across trials 
(i.e., differing population ranges), making comparisons and the identification of best techniques 
come with a cavoite. While keto diets seem to carry a low risk of serious ad- verse events, side 
effects, which may include fatigue, feelings of detachment or fogginess, anxiety, headaches, 
insomnia, and irritability, have not been thoroughly studied.  
Despite these limitations, results were quite similar across studies, showing beneficial 
effects in many patients. In general, however, there is insufficient evidence to make a 
recommendation regarding the role of CAM therapies in epilepsy. While keto diets, for instance, 
are FDA approved and backed by the American Academy of Neurology, there are no guidelines 
on other CAM therapy use. Homeopathy, osteopathy, acupuncture, EEG biofeedback, 
naturopathic treatment, yoga, kinesiology, vitamins and herbal remedies and neurofeedback may 
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8. Conclusion 
Many uncertainties remain regarding alternative treatments for epilepsy, including the 
optimal cognitive or behavioral approaches, the ideal duration of treatment, the time course of 
potential improvement, and the types of patients who may benefit most. Evidence of the 
effectiveness of CAM therapy in gray literature29,26,12,13  and anecdotal material similar to that of 
Charlotte Figi case study, led me to consider how benefits are supported in experimental 
studies. However, review of these studies demonstrate research gaps. We must consider 
funding and medical precedent to further investigate the benefits of CAM therapies in pediatric 
epileptic patients. Unfortunately, participation in such research may be limited by the need to 
travel for training or therapy, economic burden, unemployment, and many more unlike the 
ease of taking a pill. Nevertheless, CAM methods offer certain advantages. They tend to be less 
expensive, are non-invasive, lack serious side effects, require little technology, are more 
accessible, and maintain a great amount of seizure control.  
 
In closing, reference to the previously addressed personal story of Charlotte Figi, will aid 
to bring this analysis to focus. Charlotte Figi’s was diagnosed with epilepsy at 3 months, 
prescribed seven or more heavy-duty AEDs, and developed both cognitive and neurological 
impairment. Abnormal electroencephalography (EEG) readings displayed an occurrence of more 
than 300 episodes a week. Aside from those recurrent seizures, neurologic tests diagnosed her 
with a rare, yet severe condition known as Dravet Syndrome. Through an adjunctive therapy 
with a high concentration of cannabidiol (9)- tetrahydrocannabinol (CBD: THC), Charlotte’s 
seizure frequency reduced from nearly 50 convulsive episodes a day to two or three nocturnal 
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convulsions per month.22 Charlotte represents as a case study of the most severe epileptic 
complications which significantly improved with the use of an alternative treatment method. 
Empirical data on the use of adjunctive therapies like THC and CBD to gauge therapeutic 
success could not be gathered due to the lack of published studies.  
 
Recently, healthcare professionals and scientific researchers have requested 
governmental funds and academic facilities to house their research on CAM therapies and 
Alternative/Osteopathic Medicine (i.e. Difficulties in Treatment and Management of 
Epilepsy…). Charlotte, a little girl who suffered from SCN1A-confirmed Dravet Syndrome, 
sparked a revolutionary change in healthcare as we know it for alternative means of medicine. 
For the purpose of continuing the revolutionary legacy of little Charlotte Figi, this meta-analysis 
was to conduct a research synthesis of studies that analyze the efficacy of CAM methods on the 
overall therapeutic success in epileptic patients. More research on the efficacy of CAM use for 


















22 Maa et. al., 2014 
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Appendix 
Definition of Terms: 
ICD-10 Code G40: A brain disorder characterized by episodes of abnormally increased neuronal 
discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic 
dysfunction. These episodes may or may not be associated with loss of consciousness or 
convulsions. 
CAM: Complementary and Alternative Medicine; a group of diverse medical and health care 
systems, practices, and products that are not presently considered to be part of conventional 
medicine 
 
AED: Antiepileptic Drugs; diverse group of pharmacological agents used in the treatment of 
epilepsy 
 
ADE: Adverse Side Effects 
 
Comprehensive Neurobehavioral CNB: A set of assessments and treatments addressing 
biological mechanisms of underlying behavioral disorders and psychological conditions 
 
Polytherapy: means of overtreatment in epilepsy, excessive number or amount of AED(s) given 
resulting in suboptimal risk-to-benefit balance 
 
Monotherapy: single drug treatment in epilepsy 
 
Covidence: systematic meta-analysis review manager  
 
Osteopathic Medicine: Medical discipline with emphasis on the interrelated unity of all systems 
in the body; a whole person approach to medicine.  
 
Homeopathic Medicine: Medical discipline based on the belief that the body can cure itself 
 
Refractory Seizures: The persistence of seizures on three or more antiepileptic drugs in full 
doasage and total compliance over a period of 3 years 
 
Generalized Seizures: Abnormal electrical activity causing a seizure begins in both halves of the 
brain at the same time.  
 
Focal Seizures/Complex Partial Seizures: A seizure occurs in just one area of the brain 
 
Quality of Life: Greater than 50% reduction of Epileptic episodes. The standard of health, 
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Heteroscedasticity: Statistical phrase that refers to the circumstance in which the variability of a 
variable is unequal across a range of values.  
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